Evidence map›Paper›PMID 34753227›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2021

[Comparison of single infusion of anti-BCMA versus combined infusion of anti-CD19 chimeric antigen receptor T cells for immune reconstruction in relapsed/refractory multiple myeloma].

J Ge, T T Zhao, C Y Wan, J Y Xia, S Y Guo, M X Yu, J Chen, Y Wang, K L Xu, Z Y Li

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

J GeDepartment of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.
T T ZhaoDepartment of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.
C Y WanDepartment of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.
J Y XiaDepartment of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.
S Y GuoDepartment of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.
M X YuDepartment of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.
J ChenDepartment of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.
Y WangDepartment of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.
K L XuDepartment of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.
Z Y LiDepartment of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.
Xuzhou Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Multiple MyelomaReceptors, Chimeric AntigenB-Cell Maturation AntigenHumansImmunotherapy, AdoptiveNeoplasm Recurrence, LocalT-LymphocytesB-Cell Maturation AntigenReceptors, Chimeric AntigenChimeric antigen receptor T cellsImmune reconstructionMultiple myeloma

Identifiers

PMID34753227
PMCPMC8607032
OpenAlexW3213567893

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.